GAfPA Blog

The GAfPA Patient Advocacy Blog

Mapping Report Reveals Access Disparities among European Patients

How accessible is your health care?  It all depends upon where you live, as a new report from the European Federation of Crohn’s & Ulcerative Colitis Associations confirms. With the help of 32 member associations, the federation worked from October 2016 to December 2017 to examine patients’ access to innovative medicine across 31 European countries.  … Continued

Europeans Work to Turn Health Care Rights into Realities

by Brian Kennedy, Executive Director, Global Alliance for Patient Access Declaring equal rights is a noble gesture.  But history teaches us that it is just the first step in a complex, years-long process – actually establishing and protecting those rights. I was reminded of this reality just recently, when I spoke at a meeting of the … Continued

Eventos Latino Americanos

La Alianza Global se está preparando para compartir temas centrales de acceso de los pacientes en dos importantes eventos de política de América Latina este año. Reunión G20 ARGENTINA El G20 es el principal foro internacional para la cooperación económica, financiera y política. Los lideres mundiales participan en esto. Es un espacio clave para el … Continued

Upcoming Latin America Events

The Global Alliance is gearing up to share central issues of patient access in two major Latin American policy events this year. G20 ARGENTINA Meeting The G20 is the main international forum for economic, financial and political cooperation. World leaders participate in it. It is a key space for debate, decision-making and coordination on policies … Continued

Revamped EudraVigilance System Could Improve Drug Safety Reporting

  Preventable drug safety issues caused nearly 200,000 deaths across the European Union in 2017.  Now the European Medicines Agency is working to address that statistic by improving its drug track-and-trace system, known as EudraVigilance.     The EudraVigilance system compiles data about side effects caused by drugs that are either in the marketplace or … Continued

Are Regulators Too Hasty in Approving Cancer Drugs?

The British Medical Journal ignited debate earlier last month when it announced that about half of cancer drugs approved by the European Medicines Agency don’t improve survival or quality of life.  The claim begs several complex question: How can regulators evaluate drugs both quickly and effectively?  And whose values should determine access to drugs for … Continued

“Fast Facts” on Pharmacovigilance Tackles Drug Safety Issues

Drug safety issues have caused more than 200,000 patient deaths in the EU. And one in three U.S. drugs may have safety issues, explains a new “Fast Facts” from the Global Alliance for Patient Access.   The paper explores how countries track and trace prescription drug side effects – and why advanced medicine demands a stronger … Continued